Starpharma Holdings
- Short interest
- 0.03%
- −0.01 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 158.1K
- Shares on issue
- 479.739M
Starpharma Holdings (SPL) Short Interest
Starpharma Holdings (ASX:SPL) had 0.03% of shares reported as short positions as of 8 Oct 2026, representing 158,145 shares. Starpharma Holdings operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Starpharma Holdings
Starpharma Holdings is an Australian biotechnology company focused on developing dendrimer technology for pharmaceutical and life science applications. Their proprietary dendrimer platform is used to improve drug delivery, enhance drug efficacy, and create new pharmaceutical products. The company's market position is built on its innovative technology and partnerships with pharmaceutical companies.
Company profile →Starpharma Holdings (ASX:SPL) has 0.03% of its shares on issue reported as short positions as of 8 Oct 2026, or about 158,145 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.08 percentage points. Its highest recorded short interest was 5.92% in September 2013. SPL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads SPL today
- Zanger BreakoutWatchScore 40rank 225 of 1942
- CAN SLIMWatchScore 33rank 269 of 1541
- Minervini Trend TemplateTriggeredScore 81rank 18 of 1716
- Crowded-Short BreakoutWatchScore 19rank 374 of 1502
- Quality compoundersWatchScore 48rank 143 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
SPL fundamentals
In the year to 30 Jun 2026, Starpharma Holdings (ASX:SPL) recorded revenue of A$12.1M and a net loss after tax of A$7.5M. A year earlier it recorded revenue of A$4.9M and a net loss after tax of A$10.0M. Year-on-year growth: revenue +145.3% (FY). Net margin −62.0%, return on equity −45.6% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest SPL news
All news- Change in substantial holding
asx · 6 Oct 2026
- Notice of Annual General Meeting/Proxy Form
asx · 5 Oct 2026
- What Does Starpharma’s (ASX:SPL) New Share Quotation Mean? - Kalkine Media
googlenews · 4 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss SPL
Start a research thread or post the first pulse update